Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120 clinical trials
How each study uses Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 4
Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Instituto de Investigación Hospital Universitario La Paz (1) · The First Affiliated Hospital of Soochow University (1) · Hebei Senlang Biotechnology Inc., Ltd. (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young AdultsRecruitingPhase 1Instituto de Investigación Hospital Universitario La PazNCT06709469Written as Autologous CD19/CD22 CAR T cells
- Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT04029038Written as Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
- GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05797948Written as CD19/CD22 CAR-T
- Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingPhase 1/2Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT04499573Written as CD19/CD22 CAR-T
- Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic LeukemiaStatus unknownEarly Phase 1Hebei Senlang Biotechnology Inc., Ltd.NCT05225831Written as Autologous CD19/CD22 Chimeric Antigen Receptor T-cells